TME Pharma N.V. announced a clinical update on survival of newly diagnosed glioblastoma patients in the GLORIA expansion arm evaluating NOX-A12, TME Pharma's CXCL12 inhibitor, in combination with standard of care radiotherapy and anti-VEGF, bevacizumab. After 12 months on study (median), 83% of patients (5 of 6) are still alive. With treatment or follow-up for these patients continuing, median overall survival (mOS) has not yet been reached.

The 12-month timepoint is an important landmark for assessment since it exceeds the expected survival of approximately 10 months for patients with MGMT unmethylated tumors and incomplete resection.